Lexaria Bioscience begins dosing for GLP-1 human pilot study #3

Lexaria Bioscience announced that dosing has begun, for human pilot study #3, investigating a DehydraTECH-processed version of the dual action GLP-1 + GIP Zepbound in an oral dose format. The Study is being conducted in up to 10 healthy volunteers. The initial seven day dosing phase of either an oral DehydraTECH-processed tirzepatide capsule or a single injected tirzepatide dose is scheduled to be completed on October 13th. After a multi-week washout period, the second seven day dosing phase will be administered in mid-November where subjects will receive the alternate treatment condition than what was received during the initial dosing phase. No serious adverse events have been observed thus far during this initial dosing phase. Tolerability, blood absorption levels and blood sugar control will all be evaluated in this Study. The DehydraTECH compositions for this Study were compound-formulated using commercially available Zepbound injectable formulation as the tirzepatide input material. In two previous human pilot studies, Lexaria has evidenced that processing of semaglutide with DehydraTECH and administered in an oral format, shows improvements in absorption rates and a reduction in both blood sugar and in adverse events, as compared to the Rybelsus tablet. The two drugs, semaglutide and tirzepatide are believed to comprise over 90% of all revenue generated in the GLP-1 sector today. In pilot Study #3, Lexaria is hopeful of evidencing meaningful absorption rates of tirzepatide in a swallowed oral format, which is not available in the market today since it is currently administered only by injection.